Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00496782 · ClinicalTrials.gov registry record · Phase 1

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

A Phase 1 study, sponsored by ViiV Healthcare.

Terminated
Registry status
Phase 1
Development phase
16
Enrollment target

NCT00496782 is a Phase 1 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00496782, a Phase 1 study, was terminated before completion, sponsored by ViiV Healthcare.

TERMINATED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

The purpose of this pilot study is to determine whether there is a correlation between viral load reduction (at Day 4, 7 or 14) following a short course (14 days) of Maraviroc added to a failing regimen, and the R5 result of the TrofileTM assay at screening.

Interventions

  • DRUG maraviroc
  • PROCEDURE Trofile Assay and HIV RNA quantification assay

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2007-07
Est. Completion 2008-10
Phase Phase 1

Sponsor

ViiV Healthcare

182 total trials

What the Registry Record Tells You About NCT00496782

The ClinicalTrials.gov registry entry for NCT00496782 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which maraviroc is the first listed.

NCT00496782 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00496782 about?

NCT00496782 is a clinical study titled "Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay". The purpose of this pilot study is to determine whether there is a correlation between viral load reduction (at Day 4, 7 or 14) following a short course (14 days) of Maraviroc added to a failing regimen, and the R5 result of the TrofileTM assay at screening.

What is the current status of trial NCT00496782?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-07. Estimated completion is 2008-10.

What interventions are being tested in trial NCT00496782?

The interventions under investigation include: maraviroc (DRUG), Trofile Assay and HIV RNA quantification assay (PROCEDURE).

Who is sponsoring clinical trial NCT00496782?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.